🎯 3 free searches remaining
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, and rheumatology in Canada and the U.S. Key strengths include a solid gross margin of 53.6% and a manageable debt-to-equity ratio of 0.49, indicating financial stability. However, concerns arise from a low net margin of 0.3% and minimal returns on equity and assets, suggesting profitability challenges. The current ratio of 1.12 is adequate, but the quick ratio of 0.62 indicates potential liquidity issues. Overall, while the company shows promise, its profitability metrics warrant caution.
Loading financial metrics...
Revenue decreased 9.2% year-over-year from $109.5M to $99.4M.
Company went from $3.6M profit to $-272K loss compared to last year.
Strong gross margin of 53.9% reflects healthy unit economics.
Strong cash flow conversion with 17.5% of revenue converting to operating cash.
Low debt-to-revenue ratio of 25.5% indicates conservative financial management.
Strong free cash flow margin of 17.5% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.